Noncanonical Interplay of GLP-1 and Glucagon Receptors: Evidence from FRET cAMP Assays

Study Background and Research Question

Glucagon-like peptide-1 (GLP-1) and glucagon receptors (GLP-1R and GluR, respectively) are G protein–coupled receptors (GPCRs) that play pivotal roles in energy homeostasis, insulin secretion, and the pathophysiology of type 2 diabetes. Traditionally, these receptors have been regarded as highly selective for their respective ligands, with GLP-1R mediating the incretin effect in pancreatic β-cells and GluR promoting hepatic glucose output. However, recent clinical and preclinical findings suggest that ligand promiscuity and receptor crosstalk may underlie some of the complex, context-dependent effects observed in metabolic regulation. Chepurny et al. (2019) sought to systematically dissect the degree to which glucagon, GLP-1, and their respective agonists and antagonists cross-activate or inhibit each other's receptors under physiologically and pharmacologically relevant conditions.

Key Innovation from the Reference Study

The central innovation of this study lies in its use of high-throughput FRET-based assays to monitor cAMP responses as a readout for receptor activation in live cells. By combining molecular modeling with these quantitative assays, the authors uncovered that glucagon is not strictly a GluR-selective ligand but can also function as a nonconventional agonist of the GLP-1 receptor—an effect previously underappreciated in the field. Furthermore, they demonstrated that commonly used antagonists such as exendin(9–39) (Ex(9–39)) and allosteric GluR inhibitors can exhibit off-target antagonism at the GLP-1R at higher concentrations. These findings urge a reevaluation of both experimental design and interpretation in GLP-1 receptor signaling research.

Methods and Experimental Design Insights

Chepurny et al. utilized a robust suite of high-throughput FRET (Förster resonance energy transfer) assays to measure cAMP accumulation—a sensitive proxy for GPCR activation—in INS-1 832/13 pancreatic β-cell lines. The study employed a panel of ligands and antagonists, including GLP-1, glucagon, Ex(9–39), LY2409021, MK 0893, and des-His1-[Glu9]glucagon. Systematic ligand titrations and antagonist co-incubations allowed for quantitative mapping of agonist and antagonist potencies and selectivities. Complementary molecular modeling provided structural context for observed pharmacological phenomena, supporting the mechanistic basis for receptor crosstalk and triagonism.

Protocol Parameters

• Cell line selection: INS-1 832/13 pancreatic β-cells expressing both GLP-1R and GluR.
• Ligand titration: Dose-response assays with GLP-1, glucagon, and peptide antagonists performed over a broad concentration range to reveal off-target effects.
• cAMP detection: FRET-based biosensor assays allow for real-time quantification of intracellular cAMP.
• Antagonist combinations: Co-application of Ex(9–39) with des-His1-[Glu9]glucagon to probe dual receptor engagement.
• Molecular modeling: In silico docking and structure-activity analysis to predict binding modes and selectivity profiles.

Core Findings and Why They Matter

The study's results reveal several critical insights for the field of metabolic regulation studies:

• Noncanonical GLP-1R activation by glucagon: At high local or pharmacological concentrations, glucagon acts as a partial agonist at the GLP-1R, thereby blurring the classical distinction between receptor selectivity. This cross-activation could be especially relevant in the microenvironment of pancreatic islets, where local concentrations may transiently rise.
• Antagonist promiscuity: Both Ex(9–39), a GLP-1R orthosteric antagonist, and GluR-selective allosteric inhibitors (LY2409021, MK 0893) were found to antagonize GLP-1– and glucagon-induced cAMP responses at the GLP-1R, particularly at higher doses. This suggests that commonly used antagonists in type 2 diabetes research may not be exclusively receptor-specific, potentially confounding data interpretation (Chepurny et al., 2019).
• Dual and triagonist strategies: The engineered hybrid peptide GGP817, which incorporates glucagon and a fragment of peptide YY (PYY), exhibited triagonist activity at GluR, GLP-1R, and neuropeptide Y2 receptor (NPY2R), suggesting a new paradigm for multi-receptor targeting in metabolic disease therapy.

Collectively, these findings highlight the importance of carefully validating the selectivity of agonists and antagonists used in GLP-1 receptor pathway research. They also suggest that previously published data may need to be reinterpreted in light of these nonconventional receptor interactions.

Comparison with Existing Internal Articles

Recent internal reviews provide expanded practical and mechanistic context for these findings. For example, "GLP-1 (9-36) amide: Redefining Antagonism in GLP-1R Pathway Research" delves into the nuanced inhibitory actions of GLP-1 (9-36) amide and offers guidance for optimizing antagonist protocols. Meanwhile, "Reframing GLP-1 Receptor Antagonism: Strategic Insights for Translational Researchers" synthesizes the implications of noncanonical crosstalk for translational assay development, reinforcing the need for high-specificity reagents and rigorous validation. Both articles echo the reference study's call for heightened scrutiny in interpreting receptor-targeted experiments, especially when using peptide antagonists or high-dose agonists. These resources, together with the reference study, provide a comprehensive knowledge base for designing robust GLP-1 receptor signaling research workflows.

Limitations and Transferability

While the FRET cAMP assay system and molecular modeling offer powerful platforms for dissecting receptor pharmacology, several constraints remain. The use of overexpressed or endogenously co-expressed receptors in cell lines may not fully recapitulate the receptor densities, compartmentalization, or signaling microdomains present in native tissues. Moreover, ligand concentrations employed in vitro may exceed physiological levels, and thus, the extent of noncanonical activity observed may not directly translate to in vivo systems. Finally, the study's insights are most directly applicable to GPCR-focused metabolic regulation studies; extrapolation to unrelated receptor systems should be approached cautiously.

Research Support Resources

For researchers aiming to replicate or extend GLP-1 receptor antagonist studies, GLP-1 (9-36) amide (SKU B5404) is a well-characterized peptide antagonist at the human GLP-1 receptor. Its application in high-throughput cell-based assays is supported by robust quality control and detailed handling guidance. As highlighted in recent literature and internal reviews, careful control of antagonist concentrations and storage conditions is essential for reliable results. For additional protocol advice and mechanistic insights, see the referenced internal articles. APExBIO's GLP-1 (9-36) amide remains a valuable resource for advanced studies of GLP-1 receptor signaling and metabolic disease mechanisms.